pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. per share, a rare 660% premium on LogicBio’s share price. .

Gene Editing 62

Gene Editing Gene Genome Genomics 62

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics DNA Genetic Engineering Antibody 130

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

RNA 104

RNA Genetics Dermatology Antibody 104

Drug Discovery World

MAY 11, 2023

Ubiquigent’s Sheelagh Frame, said: “It was wonderful to share experiences and thoughts about building better workplaces alongside some other inspiring women in life science.” However, she also presented thoughts in a technical update, Targeted Protein Degradation – Progress, Direction and Prospects.

Life Science 52

Life Science Genetics Vaccination Vaccine 52